Evaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome

We examined the pharmacological profile of ramosetron, a 5-HT3-receptor antagonist for irritable bowel syndrome with diarrhea, comparing it with those of other 5-HT3-receptor antagonists, alosetron and cilansetron, and the anti-diarrheal agent loperamide. Ramosetron showed high affinity for cloned h...

Full description

Bibliographic Details
Main Authors:	Takuya Hirata, Yoshihiro Keto, Toshiyuki Funatsu, Shinobu Akuzawa, Masao Sasamata
Format:	Article
Language:	English
Published:	Elsevier 2007-01-01
Series:	Journal of Pharmacological Sciences
Online Access:	http://www.sciencedirect.com/science/article/pii/S1347861319342525

Similar Items

Inhibitory Effects of Ramosetron, a Potent and Selective 5-HT3–Receptor Antagonist, on Conditioned Fear Stress–Induced Abnormal Defecation and Normal Defecation in Rats: Comparative Studies With Antidiarrheal and Spasmolytic Agents
by: Takuya Hirata, et al.
Published: (2008-01-01)

The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)
by: Yang Won Min, et al.
Published: (2015-05-01)

Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
by: Chiba T, et al.
Published: (2013-07-01)

Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials
by: Qingqing Qi, et al.
Published: (2018-01-01)

Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
by: Esther Colomier, et al.
Published: (2021-02-01)

Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms
by: Xiufang Cui, et al.
Published: (2021-11-01)

The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Ameliorative Effect of Solifenacin Succinate (Vesicare ®), a Bladder-Selective Antimuscarinic Agent, on Overactive Bladder Symptoms, Especially Urgency Episodes
by: Akiyoshi Ohtake, et al.
Published: (2010-01-01)

Prevention of microemulsion propofol injection pain: a comparison of a combination of lidocaine and ramosetron with lidocaine or ramosetron alone
by: Hyun-Young Lee, et al.
Published: (2011-07-01)

Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
by: Toshihiko Tomita, et al.
Published: (2022-11-01)

Effect of ramosetron on shivering during spinal anesthesia
by: Min Soo Kim, et al.
Published: (2010-03-01)

Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions
by: David J. Cangemi, et al.
Published: (2019-10-01)

Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents
by: Anita Sainsbury, et al.
Published: (2011-03-01)

Relationship between cognitive appraisals of symptoms and negative mood for subtypes of irritable bowel syndrome
by: Nomura Shinobu, et al.
Published: (2008-04-01)

Pathogenetic Substantiation of the Therapeutic Impact on Microbiota in Irritable Bowel Syndrome
by: Yu. O. Shulpekova, et al.
Published: (2019-09-01)

Potential neuro-immune therapeutic targets in irritable bowel syndrome
by: Maite Casado-Bedmar, et al.
Published: (2020-04-01)

Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease
by: Alessandra Lo Presti, et al.
Published: (2019-07-01)

Defining the irritable bowel
by: Kee Huat Chuah, et al.
Published: (2022-04-01)

The irritable bowel syndrome
by: Vaerenbergh Wim, et al.
Published: (1998-01-01)

Irritable Bowel Syndrome
by: Jae Hak Kim, et al.
Published: (2019-02-01)

Irritable bowel syndrome
by: Vasile Valeriu LUPU, et al.
Published: (2016-03-01)

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
by: Mauro Bafutto, et al.
Published: (2011-03-01)

Irritable brain caused by irritable bowel? A nationwide analysis for irritable bowel syndrome and risk of bipolar disorder.
by: Chia-Jen Liu, et al.
Published: (2015-01-01)

Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis
by: Eric D. Shah, et al.
Published: (2021-01-01)

Ramosetron as a Treatment for Cyclic Vomiting Syndrome: A Small-Scale Patient Trial
by: Toshiyuki Hikita MD, PhD, et al.
Published: (2020-11-01)

Effects of Intestinal Flora on Irritable Bowel Syndrome and Therapeutic Significance of Polysaccharides
by: Yang Ye, et al.
Published: (2022-05-01)

Irritable bowel syndrome – diagnostic and therapeutic recommendations considering the place of antispasmodics
by: Anna Cybulska
Published: (2019-11-01)

Review: Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome
by: Alexandru Gaman, et al.
Published: (2009-05-01)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
by: Iorio N, et al.
Published: (2015-06-01)

Psychological profiles of irritable bowel syndrome patients with different phenotypes
by: Michel Bouchoucha, et al.
Published: (2020-10-01)

Understanding irritable bowel syndrome /
by: 262617 Darnley, Simon, et al.
Published: (2003)

Irritable Bowel Syndrome and Resilience
by: Mihaela Fadgyas Stanculete, et al.
Published: (2023-06-01)

IRRITATED BOWEL SYNDROME IN CHILDREN
by: V. F. Privorotskiy, et al.
Published: (2012-05-01)

Postinfection irritable bowel syndrome
by: A I Papfenov, et al.
Published: (2009-02-01)

Diets and Irritable Bowel Syndrome
by: Zahra Darabi, et al.
Published: (2019-09-01)

The epidemiology of irritable bowel syndrome
by: Canavan C, et al.
Published: (2014-02-01)

Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice
by: Susan Lucak, et al.
Published: (2017-02-01)

Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes
by: Jonathan P. Jacobs, et al.
Published: (2023-01-01)

Prevention of propofol injection pain: Comparison between lidocaine and ramosetron
by: Dipali Singh, et al.
Published: (2014-01-01)

Efficacy of ramosetron in combination with polyethylene glycol of preparing for a colonoscopy
by: Min Kyu Kang, et al.
Published: (2019-05-01)

Mucosal Microbiome Profiles Polygenic Irritable Bowel Syndrome in Mestizo Individuals
by: Rene Arredondo-Hernández, et al.
Published: (2020-03-01)